ARTICLE SUMMARY:
Over the past half-decade, no life science company has achieved the growth in shareholder value that Johnson & Johnson has. Much of that, however, has come from a reinvigorated pharmaceutical business. As change and headwinds confront the medical device industry, J&J CEO Alex Gorsky talks about J&J’s medtech businesses and where they fit in the company’s portfolio.
Over the past five years, only six companies have increased shareholder value by $175 billion or more. Five of them are obvious: tech giants Amazon, Google, Facebook, Microsoft, and industry’s leading value investor, Berkshire Hathaway. The sixth company? Johnson & Johnson .
